OPTION DESIGNATION CHECKLIST FOR OPTIONS ON PHYSICALS—Continued

Criteria	Applicable commission rule, 17 CFR	Standard	Met by exchang rule number
5. Option expiration	33.4(d)(1)	Options expire not less than one business day before the earlier of the last trading day or the first notice day of any futures contract in the same or a related commodity, except for cash-settled futures contracts..	

(6) *Other required information.* As requested, a board of trade shall submit additional evidence, information, data or stipulations relating to whether a contract meets, initially or on a continuing basis, the public interest standard contained in section 5(g) of the Act, the economic purpose standard of § 33.4(a)(5)(i) of this chapter, or any other requirement for designation under the Act or Commission rules.

Issued in Washington, DC this 22nd day of January, 1992, by the Commodity Futures Trading Commission.

Jean A. Webb,

Secretary of the Commission.

[FR Doc. 92-1910 Filed 1-29-92; 8:45 am]

BILLING CODE 6351-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 310

[Docket No. 89N-0525]

Status of Certain Over-the-Counter Drug Category II and III Active Ingredients; Technical Amendment

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; technical amendment.

SUMMARY: The Food and Drug Administration (FDA) is amending the regulations regarding the status of certain over-the-counter (OTC) drug Category II and III active ingredients. This final rule makes nonsubstantive corrections to the final regulations that were published in the **Federal Register** of November 7, 1990 (55 FR 46914). That final rule listed the names of several active ingredients incorrectly. This document corrects those errors and provides clarification of the final rule for certain OTC drug products.

EFFECTIVE DATE: January 30, 1992.

FOR FURTHER INFORMATION CONTACT: William E. Gilbertson, Center for Drug Evaluation and Research (HFD-210), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-295-8000.

SUPPLEMENTARY INFORMATION: This document amends the final rule concerning drug products containing certain active ingredients offered OTC for certain uses in 21 CFR part 310 (as set forth in the **Federal Register** of November 7, 1990 (55 FR 46914)). That final rule lists several active ingredients incorrectly. This final rule corrects those errors in the regulations. As noted above, these amendments institute changes that are nonsubstantive in nature. Because the amendments are not controversial and because, when effective, they provide clarification of a final rule for OTC drug products, FDA finds that the usual notice and comment procedures are unnecessary.

List of Subjects in 21 CFR Part 310

Administrative practice and procedure, Drugs, Labeling, Medical devices, Reporting and recordkeeping requirements.

Therefore under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR part 310 is amended as follows:

PART 310—NEW DRUGS

1. The authority citation for 21 CFR part 310 continues to read as follows:

Authority: Secs. 201, 301, 501, 502, 503, 505, 506, 507, 512-516, 520, 601(a), 701, 704, 705, 706 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321, 331, 351, 352, 353, 355, 356, 357, 360b-360f, 360j, 361(a), 371, 374, 375, 376); secs. 215, 301, 302(a), 351, 354-360F of the Public Health Service Act (42 U.S.C. 216, 241, 242(a), 262, 263b-263n).

§ 310.545 [Amended]

2. Section 310.545 *Drug products containing certain active ingredients offered over-the-counter (OTC) for certain uses* is amended in paragraph (a)(1) by removing the entry "Chlorhydroxyquinoline" and alphabetically adding the entry "Cloxyquin"; by removing from paragraph (a)(2) the entry "Acidulated sodium phosphate"; by removing from paragraphs (a)(6)(i) and (a)(6)(ii) the entry "Thenyldiamine" and adding in their place the entry "Thenyldiamine hydrochloride"; by removing from paragraph (a)(7) the entries "Alkyl isoquinolinium", "Lauryl isoquinolinium", and "Methylbenzethonium" and adding in their place the entries "Alkyl isoquinolinium bromide", "Lauryl isoquinolinium bromide", and "Methylbenzethonium chloride", respectively; by removing from paragraph (a)(8) the entries "Dihydroxyaluminum", "Glutamic acid", and "Homatropine", and adding in their place the entries "Dihydroxyaluminum sodium carbonate", "Glutamic acid hydrochloride", and "Homatropine methylbromide", respectively; by removing from paragraph (a)(12)(iv) the entry "Prune concentrate" and adding in its place the entry "Prune concentrate dehydrate".

Dated: January 24, 1992.

Michael R. Taylor,

Deputy Commissioner for Policy.

[FR Doc. 92-2229 File 1-29-92; 8:45 am]

BILLING CODE 4160-01-M

DEPARTMENT OF THE TREASURY

Internal Revenue Service

26 CFR Parts 1 and 602

[T.D. 8394]

RIN 1545-A037

Proceeds of Bonds Used for Reimbursement

AGENCY: Internal Revenue Service, Treasury.

ACTION: Final regulations.

SUMMARY: This document contains final regulations that provide guidance as to when the allocation of bond proceeds to reimburse expenditures previously made by an issuer is treated as an expenditure of the bond proceeds. When bond proceeds are "spent," they are no longer subject to arbitrage rebate, arbitrage yield limitations, and certain other limitations. Changes to the applicable law were made by the Tax Reform Act of 1984 and the Tax Reform Act of 1986.